OR-OREGON-SYMPHONY
9.2.2021 19:17:04 CET | Business Wire | Press release
The Oregon Symphony is proud to announce that acclaimed Austrian-born conductor David Danzmayr will serve as its next Music Director with the launch of its 2021-2022 season and the symphony’s 125th anniversary year. Regarded as one of today’s most gifted conductors, Danzmayr recently served as Chief Conductor of the Zagreb Philharmonic Orchestra and Music Director of ProMusica Chamber Orchestra. He has conducted orchestras at some of the world's most prominent concert halls in Germany, Italy, Scotland and major cities across the United States. Danzmayr follows esteemed Music Director Carlos Kalmar , who has held the position with the Oregon Symphony for the last 18 years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005045/en/
“We are thrilled to have David joining the Oregon Symphony as a creative leader with a unique artistic vision,” shares Scott Showalter, Oregon Symphony President and CEO. “His inaugural season, with the implementation of his Creative Alliance, reflects his desire to embrace wide-ranging cultures while inspiring and challenging audiences, and is sure to open another rich chapter in Oregon Symphony history.”
Danzmayr holds a strong belief that a composer’s musical expression is shaped by their personal environment, family heritage and culture, which will be reflected in the Symphony’s 2021-2022 season programming and launch of the Oregon Symphony Creative Alliance. Danzmayr’s vision unites a wide-range of musical innovators to create vibrant work from unique perspectives. Under Danzmayr, the Creative Alliance will feature extraordinary artists and cultural thought leaders, including Nathalie Joachim, Gabriela Lena Frank, Jun Märkl, Gabriel Kahane, Simone Lamsma and Johannes Moser.
“The Oregon Symphony is one of the county's top orchestras, with talented musicians and a passionate community, and I am honored to have been selected as its next Music Director,” says Danzmayr.” As part of my agenda, I’m committed to building upon the Symphony's high standard of excellence with music that is meaningful to Oregon audiences.”
Danzmayr will join the four-time Grammy-nominated Oregon Symphony for its pivotal 125th anniversary, marking a profound milestone as the Symphony continues its legacy as the oldest orchestra in the Western United States.
"Oregon is proud to share 125 years with our beloved Oregon Symphony, and I want to personally welcome David Danzmayr as its new Music Director,” says Gov. Kate Brown. “The Oregon Symphony is one of our state’s artistic treasures, and the last 18 years with Carlos Kalmar as Music Director have been phenomenal. I can't wait to see what the symphony achieves under David’s leadership."
The Oregon Symphony will announce its 2021-2022 season in March 2021. For information about David Danzmayr, visit www.orsymphony.org/Danzmayr .
About Oregon Symphony
Led by Music Director Carlos Kalmar, the Oregon Symphony serves more than 235,000 people annually through concerts and award-winning education and community programs. The Symphony continues to innovate through series such as SoundSights, Sounds of Home and SoundStories. Follow the Oregon Symphony on Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom